Rxsight, Inc., a company dedicated to providing customized vision to patients following cataract surgery, has announced its preliminary first quarter 2025 revenue and revised full-year 2025 guidance.
Preliminary first quarter 2025 revenue is expected to be approximately $37.9 million, marking a 28% increase compared to the first quarter of the previous year. However, it also represents a 6% decrease compared to the fourth quarter of 2024. This growth is driven by the sale of 27,579 light adjustable lenses (LAL™/LAL+®), reflecting a 36% increase in procedure volume compared to the first quarter of 2024. Additionally, the sale of 73 light delivery devices (LDD™s) expanded the installed base to 1,044 LDDs as of March 31, 2025, signifying a 43% increase compared to the installed base at the end of the first quarter of 2024.
The company has revised its 2025 full-year revenue and operating expense guidance as follows: Revenue is now expected to be in the range of $160.0 million to $175.0 million, a decrease from the previous guidance range of $185.0 million to $197.0 million, representing implied growth of 14% to 25% compared to 2024. Operating expenses are projected to be in the range of $150.0 to $160.0 million, down from the previous range of $165.0 million to $170.0 million, now representing an implied increase of 10% to 18% compared to 2024. * Operating expenses also include non-cash stock-based compensation expense, which is now projected to be in the range of $27.0 million to $30.0 million, compared to the previous range of $22.0 million to $25.0 million.
The company is set to announce unaudited financial results for the first quarter of 2025 on Wednesday, May 7, 2025. Management will discuss these results during a conference call following the announcement.
Rxsight, Inc. will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time to discuss its preliminary first quarter 2025 revenue results and revised full-year guidance. Additionally, the company plans to host another conference call shortly after the market close on Wednesday, May 7, 2025, to discuss the unaudited financial results for the first quarter of 2025.
The Rxsight® Light Adjustable Lens system, including the LAL™/LAL+®, and the Rxsight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Today the company's shares have moved -38.6% to a price of $16.02. For more information, read the company's full 8-K submission here.
